Spyre Therapeutics Cash from Other Financing Activities (Quarterly) Analysis

Spyre Therapeutics, Inc. (SYRE)

43.72 +0.27 (+0.62%) USD | NASDAQ | Feb 25, 12:27

View Cash from Other Financing Activities (Quarterly) for SYRE.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Cash from Other Financing Activities (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Cash from Other Financing Activities (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Cash from Other Financing Activities (Quarterly) Benchmarks

Start Trial

PTC Therapeutics, Inc.	Upgrade
Tandem Diabetes Care, Inc.	Upgrade
ACADIA Pharmaceuticals, Inc.	--
Alnylam Pharmaceuticals, Inc.	Upgrade
Savara, Inc.	--